📊 MAJI Key Takeaways
Is MAJI a Good Investment? Thesis Analysis
Nextel Medical is in severe financial distress with zero revenue, negative stockholders' equity of -$463.3K, and minimal assets of $1.0K against liabilities of $464.3K. The company is technically insolvent with negative operating cash flow and no discernible business operations, representing an extreme risk of total loss.
Why Buy MAJI? Key Strengths
- No strengths identified
MAJI Investment Risks to Consider
- Zero revenue and no operational business activity
- Negative stockholders' equity indicating technical insolvency
- Liabilities exceed assets by $463.3K with minimal cash runway
- Negative operating cash flow of -$61.3K with no ability to fund operations
- Negligible asset base of $1.0K provides no liquidation value protection
- Data is stale as of July 31, 2020 with no recent insider activity indicating abandonment
Key Metrics to Watch
- Return to positive revenue or business activity
- Debt restructuring or capital injection
- Total asset value trend
MAJI Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
MAJI Profitability Ratios
MAJI vs Default Sector
How Exousia Pro, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MAJI Overvalued or Undervalued?
Based on fundamental analysis, Exousia Pro, Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MAJI Balance Sheet & Liquidity
MAJI 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Exousia Pro, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
MAJI Growth Metrics (YoY)
MAJI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2021 | N/A | $5.6K | N/A |
| Q3 2020 | N/A | $5.6K | N/A |
| Q2 2020 | N/A | $5.6K | N/A |
| Q1 2020 | N/A | $5.6K | N/A |
| Q3 2019 | N/A | -$36 | N/A |
| Q2 2019 | N/A | -$36 | N/A |
| Q3 2012 | N/A | -$19.9K | N/A |
| Q2 2012 | N/A | -$28.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MAJI Capital Allocation
MAJI SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Exousia Pro, Inc. (CIK: 0001492448)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MAJI
What is the AI rating for MAJI?
Exousia Pro, Inc. (MAJI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAJI's key strengths?
Claude: .
What are the risks of investing in MAJI?
Claude: Zero revenue and no operational business activity. Negative stockholders' equity indicating technical insolvency.
What is MAJI's revenue and growth?
Exousia Pro, Inc. reported revenue of $0.0.
Does MAJI pay dividends?
Exousia Pro, Inc. does not currently pay dividends.
Where can I find MAJI SEC filings?
Official SEC filings for Exousia Pro, Inc. (CIK: 0001492448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAJI's EPS?
Exousia Pro, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MAJI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Exousia Pro, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MAJI stock overvalued or undervalued?
Valuation metrics for MAJI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MAJI stock in 2026?
Our dual AI analysis gives Exousia Pro, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAJI's free cash flow?
Exousia Pro, Inc.'s operating cash flow is $-61.3K, with capital expenditures of N/A.
How does MAJI compare to other Default stocks?
Vs Default sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 1.8).